Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F. Grossmann, Antoni Ribas
Topics & Concepts
DosingMedicineTrametinibRandomized controlled trialMelanomaDabrafenibRandomizationMEK inhibitorInternal medicineOncologyProgression-free survivalClinical trialChemotherapyCancerVemurafenibMetastatic melanomaMAPK/ERK pathwayKinaseCancer researchBiologyCell biologyMelanoma and MAPK PathwaysHER2/EGFR in Cancer ResearchComputational Drug Discovery Methods